Evicenter
P&T meetings

Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
Last updated
217 sources

Economic information and modeling reportBudget impact model

Epidemiology and eligible population inputs

10 evidence topics · 9 sources

ICER potential budget impact analysis: eligible population and uptake

“The analysis included patients starting tavapadon as first-line treatment and patients starting tavapadon as add-on therapy to levodopa, corresponding to the two modeled populations.” (opens the source at this quote in a new tab)

“To size the first-line candidate population, we multiplied the US population averaged over the next five years (342,339,134)” (opens the source at this quote in a new tab)

“by the prevalence of Parkinson’s disease (approximately 0.34%)” (opens the source at this quote in a new tab)

“by the proportion of patients not yet treated with any pharmacologic therapy (37.6%),” (opens the source at this quote in a new tab)

“yielding 436,786 patients. To size the add-on candidate population, we multiplied the same population and prevalence by the proportion treated with levodopa (43.7%),” (opens the source at this quote in a new tab)

“yielding 508,141 patients, for a total eligible population of 944,927. For this analysis, we assumed 20% of eligible patients would initiate treatment in each of the five years, or 188,985 patients per year (87,357 first-line and 101,628 add-on).” (opens the source at this quote in a new tab)

Prevalence of Parkinson's disease among United States adults by age and insurance type, 2024

“Among U.S. adults in 2024, an estimated 1.09 million individuals have PD and approximately 120,000 have AP.” (opens the source at this quote in a new tab)

“The majority (86%) of the PD population are eligible for Medicare coverage.” (opens the source at this quote in a new tab)

CharacteristicQuoted number of persons estimated to have Parkinson's diseaseQuoted populationQuoted prevalence
Age 18 to 49 years“51,719”“141,792,556”“0.04%”
Age 50 to 64 years“222,591”“61,660,017”“0.36%”
Age 65 to 74 years“340,161”“35,223,309”“0.97%”
Age 75 years and older“478,036”“26,298,663”“1.82%”
Insurance: private“99,423”“138,862,094”“0.07%”
Insurance: Medicare“945,452”“73,280,221”“1.29%”
Overall“1,092,506”“264,974,545”“0.41%”
Antiparkinsonian drug use and drug class use among Medicare beneficiaries with prevalent Parkinson's disease, 2007 to 2010

“This was a retrospective analysis of prevalent cases of PD using annual cross‐sections of Medicare beneficiaries from 2007 to 2010.” (opens the source at this quote in a new tab)

“The majority of PD patients (range, 81–82%) were prescribed at least 1 anti‐Parkinson drug each year.” (opens the source at this quote in a new tab)

“Of the treated patients, 90% were on l‐dopa therapy. This was followed by therapy with dopamine agonists (29–31%), MAOB inhibitors (9–11%), amantadine (7–8%), COMTIs (6–8%), and anticholinergics (5–6%) (Table 2).” (opens the source at this quote in a new tab)

MeasureQuoted value, 2007Quoted value, 2008Quoted value, 2009Quoted value, 2010
Total number of patients with Parkinson's disease“9482”“9626”“9566”“9503”
Number of antiparkinsonian drug users“7721”“7872”“7835”“7725”
Use of any antiparkinsonian drug, %“81”“82”“82”“81”
Levodopa use, %“90”“90”“90”“90”
Dopamine agonist use, %“31”“31”“30”“29”
MAO-B inhibitor use, %“9”“9”“10”“11”
Amantadine use, %“8”“7”“7”“7”
COMT inhibitor use, %“8”“7”“7”“6”
Untreated share and first-line medication in newly diagnosed Parkinson's disease, United States claims, 2014 to 2017

“Incident PD cases were identified in the IBM MarketScan database between January 1, 2014 and June 30, 2017.” (opens the source at this quote in a new tab)

“Of the 113,647 patients who had at least one diagnosis code for PD in the IBM MarketScan database, 11,280 fulfilled the study criteria and were included in the US study.” (opens the source at this quote in a new tab)

“In the US, 4241 (37.6%) of the patients with PD did not have documented PD medication prescriptions filled during the study period, whilst 7039 (62.4%) patients received PD treatment during the follow-up period.” (opens the source at this quote in a new tab)

“Levodopa was the most common first-line PD treatment, prescribed to 70.1% of treated patients.” (opens the source at this quote in a new tab)

Initial medicationQuoted number (%) of treated patients
Levodopa“4932 (70.1)”
Rasagiline“579 (8.2)”
Ropinirole“357 (5.1)”
Pramipexole“324 (4.6)”
Amantadine“169 (2.4)”
Rotigotine“79 (1.1)”
First treatment class after diagnosis in incident Parkinson's disease, United States claims, 2008 to 2016

“Retrospective cohort study using claims data from the United States between 2008 and 2016.” (opens the source at this quote in a new tab)

“Out of the full PD cohort, 68,532 (81.5%) patients had insurance drug coverage (as well as medical) and were therefore eligible for treatment pattern analyses.” (opens the source at this quote in a new tab)

“Of the 49,737 (72.6%) patients whose first treatment was observed during follow-up, 70.3% were prescribed levodopa/combination therapy, making it by far the most commonly used treatment class.” (opens the source at this quote in a new tab)

“First-line use of monotherapy MAO-Bi was reported in 8.3% of patients and first-line use of amantadine was 3.1%.” (opens the source at this quote in a new tab)

First treatment classQuoted number of patientsQuoted % of patients eligible for treatment pattern analysisQuoted % of patients treated
Levodopa and levodopa combinations“34,977”“51.0”“70.3”
Dopamine agonists“7,729”“11.3”“15.5”
MAO-B inhibitors“4,112”“6.0”“8.3”
Amantadine“1,521”“2.2”“3.1”
Adjunctive treatment classes among levodopa-treated patients with and without OFF episodes, United States

“In addition to carbidopa/levodopa, patients were also prescribed antiparkinsonian treatments from other pharmacologic classes, including dopamine agonists (25%), catechol-O-methyl transferase inhibitors (17%), monoamine oxidase type B inhibitors (16%), and N-methyl-D-aspartate antagonists (13%; Table 1).” (opens the source at this quote in a new tab)

Quoted current prescribed treatment classQuoted overall (N = 722)Quoted patients without OFF episodes (n = 401)Quoted patients with OFF episodes (n = 321)
“Carbidopa/levodopa”“722 (100.0)”“401 (100.0)”“321 (100.0)”
“COMT inhibitor”“119 (16.5)”“48 (12.0)”“71 (22.1)”
“Dopamine agonist”“177 (24.5)”“73 (18.2)”“104 (32.4)”
“MAO-B inhibitor”“118 (16.3)”“50 (12.5)”“68 (21.2)”
“NMDA receptor antagonist”“90 (12.5)”“24 (6.0)”“66 (20.6)”
Concomitant medication classes at levodopa initiation among Medicare fee-for-service beneficiaries, 2017 to 2019

“The study population included 201,241 Medicare beneficiaries aged 65–90 years with PD who received at least one prescription for a carbidopa–levodopa-containing regimen.” (opens the source at this quote in a new tab)

“Medications were considered concomitant if there was a claim within 30 days of levodopa initiation on either side of the first levodopa claim, that is, 30 days before or after the first levodopa medication claim.” (opens the source at this quote in a new tab)

“The use of concomitant medications increased with increasing LEDD, specifically for dopamine agonists (6.6–13.5% for lowest LEDD group; 31.9–43.8% for highest LEDD group); COMT inhibitors (1.7–6.7% for lowest LEDD group; 5.0–14.3% for highest LEDD group); and amantadine (1.1–4.7% for lowest LEDD group; 13.8–18.3% for highest LEDD group).” (opens the source at this quote in a new tab)

Concomitant medication classLevodopa equivalent daily dose group (mg)Quoted n (%), immediate-release carbidopa-levodopaQuoted n (%), controlled-release plus immediate-release carbidopa-levodopaQuoted n (%), controlled-release carbidopa-levodopaQuoted n (%), extended-release carbidopa-levodopa
Total patients150 to 350“N = 67,851”“N = 2355”“N = 4363”“N = 918”
Total patients351 to 600“N = 57,919”“N = 5558”“N = 4065”“N = 1489”
Total patients601 to 900“N = 26,134”“N = 5801”“N = 1461”“N = 1257”
Total patients901 to 10,000“N = 14,884”“N = 5372”“N = 480”“N = 1334”
COMT inhibitors150 to 350“1730 (2.6)”“157 (6.7)”“76 (1.7)”“21 (2.3)”
COMT inhibitors351 to 600“3063 (5.3)”“414 (7.5)”“193 (4.8)”“40 (2.7)”
COMT inhibitors601 to 900“2246 (8.6)”“611 (10.5)”“112 (7.7)”“48 (3.8)”
COMT inhibitors901 to 10,000“1802 (12.1)”“770 (14.3)”“47 (9.8)”“67 (5.0)”
Dopamine agonists150 to 350“4500 (6.6)”“181 (7.7)”“379 (8.7)”“124 (13.5)”
Dopamine agonists351 to 600“8115 (14.0)”“789 (14.2)”“693 (17.1)”“276 (18.5)”
Dopamine agonists601 to 900“6377 (25.8)”“1234 (21.3)”“555 (38.0)”“348 (27.7)”
Dopamine agonists901 to 10,000“4743 (31.9)”“1749 (32.6)”“210 (43.8)”“431 (32.3)”
MAO-B inhibitors150 to 350“2411 (3.6)”“99 (4.2)”“213 (4.9)”“188 (20.5)”
MAO-B inhibitors351 to 600“5468 (9.4)”“536 (9.6)”“312 (7.7)”“350 (24.0)”
MAO-B inhibitors601 to 900“3067 (11.7)”“720 (12.4)”“180 (12.3)”“268 (21.3)”
MAO-B inhibitors901 to 10,000“1445 (9.7)”“689 (12.8)”“55 (11.5)”“271 (20.3)”
Amantadine150 to 350“770 (1.1)”“39 (1.7)”“56 (1.3)”“43 (4.7)”
Amantadine351 to 600“2457 (4.2)”“209 (3.8)”“157 (3.8)”“99 (6.7)”
Amantadine601 to 900“2155 (8.3)”“485 (8.3)”“195 (13.6)”“152 (12.1)”
Amantadine901 to 10,000“2049 (13.8)”“838 (15.6)”“88 (18.3)”“212 (15.9)”
Average daily dose of carbidopa-levodopa among Medicare fee-for-service beneficiaries, 2017 to 2019

“Patients using ER carbidopa–levodopa had the highest mean dose (1140 mg, although this is roughly equivalent to approximately 570 mg of non-ER levodopa, aligning with the other formulations due to reduced bioavailability)” (opens the source at this quote in a new tab)

“All other formulations had mean doses between 480 and 585 mg.” (opens the source at this quote in a new tab)

FormulationQuoted number of patientsQuoted mean ± SD daily dose (mg)Quoted median daily dose (mg)
Overall“201,241”“510.99 ± 365.93”“400.0”
Immediate-release carbidopa-levodopa“166,788”“480.39 ± 334.94”“400.0”
Immediate-release plus controlled-release carbidopa-levodopa“19,086”“585.52 ± 359.21”“500.0”
Controlled-release carbidopa-levodopa“10,369”“551.92 ± 296.38”“520.0”
Extended-release carbidopa-levodopa“4998”“1140.26”, “± 709.51”“980.0”
Adherence and persistence after initiation of levodopa or a dopamine agonist, United States Medicaid claims

“Our study sample of 805 Medicaid patients had an average age of 54.1 years, with 52.0% being female. Levodopa was the predominant PD medication at initiation (75.4%).” (opens the source at this quote in a new tab)

“Persistence was determined by identifying the last consecutive medication day of the initiating medication during the post-index period, without a gap in therapy of 60 days or greater. Given that we allowed for a 60-day runout period to determine a gap in therapy, persistence was assessed through day 305 of the post-index period.” (opens the source at this quote in a new tab)

“Slightly more than half (51.4%, adjusted) of levodopa patients continued use of the medication, without a gap of 60 days or greater, while only 40.6% (adjusted) of DA patients were persistent in medication use (p = 0.008) (Table 1).” (opens the source at this quote in a new tab)

MeasureQuoted adjusted value, levodopaQuoted adjusted value, dopamine agonistQuoted p value
Mean proportion of days covered (SD)“0.621 (0.322)”“0.546 (0.343)”“0.007”
Adherent patients (proportion of days covered of 0.80 or higher)“41.4%”“33.8%”“0.060”
Mean persistent days (SD)“209.5 (114.2)”“185.4 (117.8)”“0.011”
Persistent patients“51.4%”“40.6%”“0.008”
Twelve-month persistence and adherence with dopamine agonist monotherapy, United States commercial and Medicare Advantage claims

“Discontinuation was defined as a treatment gap of ≥60 days.” (opens the source at this quote in a new tab)

“A total of 283 (44.1 %) of the patients discontinued their index therapy, while 359 (55.9 %) persisted for 12 months after initiation without any change.” (opens the source at this quote in a new tab)

“The mean (SD) PDC for the overall 642 patients was 0.66 (0.3). A total of 324 (50.5 %) of patients were PDC adherent to treatment as defined by PDC ≥0.80 (Table 5).” (opens the source at this quote in a new tab)